Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 6, 2010, Pages 624-627

  dos Reis, Sabrina Thalita ^a   Villanova, Fabiola Elizabeth ^a   Andrade, Priscila Maria ^a   Pontes, José ^a   de Sousa Canavez, Juliana Moreira ^b   Sañudo, Adriana ^a   Antunes, Alberto Azoubel ^a   Dall'Oglio, Marcos Francisco ^a   Srougi, Miguel ^a   Moreira Leite, Katia Ramos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Genoa Biotechnology   (Brazil)

Author keywords

Disease susceptibility; Metalloproteinases; Polymorphism; Prognosis; Prostate cancer

Indexed keywords

GELATINASE A; GENOMIC DNA;

AGED; ALLELE; ARTICLE; CANCER STAGING; DNA SEQUENCE; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BRAZIL; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 78149364450     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.10.012     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2006. CA cancer J Clin 2006, 56:106-130.
3. Gleason D.F. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992, 23:273-279.
4. Nelson A.R., Fingleton B., Rothenberg M.L., et al. Matrix metalloproteinases: Biological activity and clinical implications. J Clin Oncol 2000, 18:1135-1149.
5. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
6. Sfar S., Saad H., Mosbah F., et al. TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet Cytogenet 2007, 172:38-44.
7. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003, 92:827-839.
8. Forget M.A., Desrosiers R.R., Beliveau R. Physiological roles of matrix metalloproteinases: Implications for tumor growth and metastasis. Can J Physiol Pharmacol 1999, 77:465-480.
9. Price S.J., Greaves D.R., Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: Role of SP-1 in allele-specific transcriptional regulation. J Biol Chem 2001, 276:7549-7558.
10. Xu E., Lai M., Lv B., et al. A Single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Commun 2004, 324:999-1003.
11. Yu C., Pan K., Xing D., et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 2002, 62:6430-6433.
12. Miao X., Yu C., Tan W., et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306 C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 2003, 63:3987-3990.
13. Yu C., Zhou Y., Miao X., et al. Functional haplotypes in the promoter of Matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004, 64:7622-7628.
14. Zhou Y., Yu C., Miao X., et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2004, 25:399-404.
15. Grieu F., Li W.Q., Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 2004, 88:197-204.
16. Wright D.K., Manos M.M. Sample preparation from paraffin-embedded tissues 1990, 153-158. Academic Press, San Diego, CA.
17. Curran S., Murray G.I. Matrix metalloproteinases in tumor invasion and metastasis. J Pathol 1999, 189:300-308.
18. Wu L.M., Zhang F., Xie H.Y., et al. MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. Clin Genet 2008, 73:273-278.
19. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today 2000, 6:146-156.
20. Tlsty T.D. Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Curr Opin Cell Biol 1998, 10:647-653.
21. Pattersson B.C., Sang Q.A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997, 272:28823-28825.
22. Zhu Y., Spitz M.R., Lei L., et al. A Single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 2001, 61:7825-7829.
23. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002, 3:409-421.
24. Zinzindohoue F., Lecomte T., Ferraz J.M., et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Cin Cancer Res 2005, 15:594-599.
25. Albayrak S., Cangüven O., Göktas C., et al. Role of MMP1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population. Urol Int 2007, 79:312-315.
26. De Cicco C., Ravasi L., Zorzino L., et al. Circulating levels of VCAM and MMP-2 may help identify with more aggressive prostate cancer. Curr Cancer Targets 2008, 8:199-206.
27. Tokuraku M., Sato H., Murakami S., et al. Activation of the precursor of gelatinase A/72KDa type collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995, 64:355-359.
28. Ross J.S., Kaur P., Sheehan C.E., et al. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003, 16:198-205.
29. Trudel D., Fradet Y., Meyer F., et al. Membrane type-1 matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: Identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 2008, 39:731-739.
30. Deng X., He G., Levine A., et al. Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic by human prostate cancer. Int J Cancer 2008, 122:209-218.